Analysis-Hims & Hers stands to gain if the FDA loosens restrictions on peptides | WTVB

The FDA advisory committee is meeting this week to consider loosening compounding restrictions on seven peptides, a move that could unlock a $2.2–3.3 billion market. Hims & Hers, which acquired peptide manufacturing capability in 2025, stands to be a major beneficiary if regulations ease, though final rulemaking could take up to a year.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.